title: [Efficacy of hepatic arterial infusion of adriamycin and mitomycin C mixed with degradable starch microspheres for liver metastasis of colorectal cancer--correlation with the mRNA expression of DNA topoisomerase-IIalpha and glutathione-S transferase-pi in primary lesions].
abstract: DNA topoisomerase-IIalpha (topo-IIalpha) is a target enzyme of adriamycin (ADM). Glutathione-S-transferase-pi is known to be correlated with the resistance of various anticancer drugs including mitomycin C (MMC) and ADM. Expression levels of topo-IIalpha and GST-pi mRNA of primary colorectal lesions were semi-quantitatively determined by the RT-PCR method in 22 patients with colorectal cancer, who underwent hepatic arterial infusion of ADM and MMC mixed with degradable starch microspheres for synchronous (n=17) or metachronous (n=5) liver metastasis. Expression of topo-IIalpha mRNA/beta-actin mRNA was 0.872+/-0.564 (mean+/-SD) in responders (PR, n=10) and 0.369+/-0.133 in non-responders (SD+PD, n=12) (p=0.047). The relative expression of GST-pi was 0.638+/-0.593 in responders and 1.014+/-0.682 in non-responders (p=0.22). These results suggest that determining the mRNA expression of topo-IIalpha is useful for predicting the efficacy for this regimen, whereas determining the mRNA expression of GST-pi is not.
authors.affiliation: Dept. of Surgery, Saitama Medical Center, Saitama Medical School.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirakawa
authors.forename: Ikuya
authors.initials: I
authors.lastname: Takeuchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakada
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Shigehisa
authors.initials: S
authors.lastname: Inokuma
authors.forename: Daijo
authors.initials: D
authors.lastname: Hashimoto
authors.forename: Hisato
authors.initials: H
authors.lastname: Osada
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Miura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001673:Biodegradation, Environmental; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004250:DNA Topoisomerases, Type II / Q000032:analysis* / Q000235:genetics; D004268:DNA-Binding Proteins; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase / Q000032:analysis* / Q000235:genetics; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007527:Isoenzymes / Q000032:analysis* / Q000235:genetics; D008113:Liver Neoplasms / Q000201:enzymology / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012333:RNA, Messenger / Q000032:analysis; D013213:Starch / Q000008:administration & dosage
chemical_list: D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D012333:RNA, Messenger; D016685:Mitomycin; D004317:Doxorubicin; D013213:Starch; C496556:GSTP1 protein, human; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; D004250:DNA Topoisomerases, Type II